NEW YORK, Dec.

NEW YORK, Sept.

Avid Radiopharmaceuticals today announced that the U.S.

Avid Radiopharmaceuticals presented clinical results on the development of a novel (18)F-labeled PET amyloid imaging agent, (18)F-AV-45, that may eventually provide a practical approach for routine brain imaging of people at risk for the development of Alzheimer's disease.

Avid Radiopharmaceuticals, Inc. announced today that new clinical imaging data highlighting the proof of concept results for the Company's lead technology will be presented at the upcoming 55th Annual Society of Nuclear Medicine (SNM) meeting in New Orleans being held the week of June 16, 2008.